Innovent Biologics, Inc.: all 216 studies

Page 1 of 3. Open to participants first (59), then studies with results posted, then the rest; newest registration first within each.

• IBI3034 Study in Healthy Adults and Patients With Primary IgA NephropathyNot yet recruitingNCT07886476Phase 1
• A Study of Efficacy and Safety of IBI3011 in Subjects With Acute Gouty ArthritisNot yet recruitingNCT07842497Phase 2
• A Study of IBI3042 in Healthy Adult ParticipantsNot yet recruitingNCT07842393Phase 1
• A Study of IBI3016 in Japanese ParticipantsRecruitingNCT07838220Phase 1
• A Study of IBI355 in Participants With Moderate-to-Severe Sjögren's DiseaseNot yet recruitingNCT07836660Phase 2
• A Study of IBI3046 in Participants With Overweight or ObesityRecruitingNCT07809945Phase 1
• IBI3042 Study in Healthy Participants and Overweight or Obese ParticipantsRecruitingNCT07793019Phase 1
• Clinical Trials of IBI3040 in Healthy Participants and Overweight or Obese ParticipantsNot yet recruitingNCT07765160Phase 1
• A Open-Label Phase in Participants With Multiple MyelomaNot yet recruitingNCT07764861Phase 2
• A Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in Participants With Moderate to Severe Atopic DermatitisRecruitingNCT07754786Phase 3
• IBI363 Combined With Bevacizumab for Advanced Colorectal CancerRecruitingNCT07722494Phase 3
• Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingNCT07643623Phase 2/3
• A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003RecruitingNCT07623798Phase 3
• A Study of IBI3031 in Participants With Thyroid Eye DiseaseRecruitingNCT07622368Phase 1
• Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid TumorsNot yet recruitingNCT07612137Phase 1/2
• Clinical Trials of IBI3035 in Healthy SubjectsRecruitingNCT07591519Phase 1
• Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid TumorsRecruitingNCT07589205Phase 1
• Safety and Preliminary Activity of BI115 in Advanced SCLCRecruitingNCT07559019Phase 1
• Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose AdministrationRecruitingNCT07554222Phase 1
• A Study of IBI3033 in Moderate-to-Severe Atopic DermatitisNot yet recruitingNCT07549984Phase 1
• A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.RecruitingNCT07490262Phase 2/3
• IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingNCT07483567Phase 2
• IBI343 in Combination Therapy for Advanced Malignant Solid TumorsRecruitingNCT07483554Phase 2
• Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/ObesityRecruitingNCT07469800Phase 3
• IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung CancerNot yet recruitingNCT07402070Phase 2
• A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic DermatitisRecruitingNCT07399067Phase 2
• IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast CancerRecruitingNCT07377643Phase 3
• A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple MyelomaRecruitingNCT07336472Phase 1/2
• A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic DermatitisRecruitingNCT07330934Phase 2
• This is a Multi-Center Study of IBI3026 in Participants With Locally Advanced, Unresectable or Metastatic Solid TumorsRecruitingNCT07327632Early Phase 1
• A Study of Picankibart in Patients With Active Psoriatic ArthritisRecruitingNCT07295509Phase 2/3
• A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMDRecruitingNCT07275840Phase 2
• A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque PsoriasisRecruitingNCT07265284Phase 3
• A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye DiseaseRecruitingNCT07265258Phase 4
• A Study of IBI362 in Chinese Adolescents With Obesity or OverweightRecruitingNCT07255209Phase 3
• Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib ProgressionNot yet recruitingNCT07199010
• A Study of IBI363 Combination Therapy in Participants With Advanced Solid TumorsNot yet recruitingNCT07124793Phase 2
• IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung CancerRecruitingNCT07122687Phase 2
• A Study of IBI3032 in Healthy ParticipantsRecruitingNCT07120425Phase 1
• A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye DiseaseRecruitingNCT07113262Phase 3
• A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)RecruitingNCT07066098Phase 3
• Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain MetastasesRecruitingNCT07008287
• IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid TumorsRecruitingNCT06974812Phase 1/2
• Study of IBI3020 Treatment in Participants With Late-Stage Solid TumorsRecruitingNCT06963281Phase 1
• A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2RecruitingNCT06931028Phase 3
• A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic TherapyRecruitingNCT06797297Phase 2
• Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung CancerRecruitingNCT06613009Phase 1
• A Study of IBI363 in Subjects With Advanced MalignanciesRecruitingNCT06468098Phase 1
• Study of IBI3005 in Subjects with Unresectable, Locally Advanced or Metastatic Solid TumorsRecruitingNCT06418061Phase 1
• IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid TumorsRecruitingNCT06349408Phase 1
• A Study of IBI363 in Subjects with Advanced Solid MalignanciesRecruitingNCT06281678Phase 2
• A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple MyelomaRecruitingNCT06083207Phase 1/2
• A Study of IBI363 in Subjects With Advanced MelanomaRecruitingNCT06081920Phase 2
• A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid TumorsRecruitingNCT05923008Phase 1/2
• A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid TumorsRecruitingNCT05636215Phase 1/2
• Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C MutationRecruitingNCT05504278Phase 1
• A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid TumorsRecruitingNCT05458219Phase 1
• First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOPNot yet recruitingNCT05280626Phase 2
• Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced MalignanciesRecruitingNCT05164458Phase 1
• Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLCCompletedNCT03629925Phase 3Results posted
• Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLCCompletedNCT03607539Phase 3Results posted
• IBI308 in Subjects With Advanced/Metastatic Solid MalignanciesCompletedNCT03568539Phase 1Results posted
• Efficacy and Safety Evaluation of IBI308 in Patients With Extranodal NK/T Cell Lymphoma PatientsCompletedNCT03228836Phase 2Results posted
• A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLCCompletedNCT03150875Phase 3Results posted
• Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line TreatmentCompletedNCT03116152Phase 2Results posted
• Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's LymphomaCompletedNCT03114683Phase 2Results posted
• Compare IBI305 and Bevacizumab on Pharmacokinetics/Safety/Immunogenicity on Healthy MaleCompletedNCT03083990Phase 1Results posted
• Evaluate the Efficacy and Safety of IBI305 in Patients With Advanced or Recurrent Non-squamous NSCLCCompletedNCT02954172Phase 3Results posted
• First in Human Study of IBI308 in Chinese Subjects With Advanced Solid TumorsCompletedNCT02937116Phase 1Results posted
• Study of IBI3016 in People With Mild or Moderate Hypertension PatientsActive, not recruitingNCT07556796Phase 1
• A Clinical Study Comparing the Bioequivalence of IBI3027 and DUPIXENT®(Dupilumab) in Healthy Chinese VolunteersActive, not recruitingNCT07502534Phase 1
• IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed HyperlipidemiaActive, not recruitingNCT07473960Phase 3
• A Mutiple-dose Study of IBI3033 in Healthy ParticipantsActive, not recruitingNCT07456839Phase 1
• Tigulixostat (IBI128) vs Febuxostat in GoutActive, not recruitingNCT07414394Phase 3
• A Dose Finding Study of IBI3016 in Mild to Moderate Hypertensive PatientsActive, not recruitingNCT07352969Phase 2
• A First-in-human, Single-ascending-dose Study of IBI3033 in Healthy ParticipantsActive, not recruitingNCT07311226Phase 1
• A Study to Evaluate the Safety, Tolerability, and Pharmacokinetic of IBI3011Active, not recruitingNCT07295496Phase 1
• A Study of IBI3032 in Chinese Participants With Overweight or ObesityActive, not recruitingNCT07170319Phase 1
• A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or ObesityCompletedNCT07160400Phase 1
• A Study of IBI3032 in Chinese Healthy SubjectsCompletedNCT07134127Early Phase 1
• Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe ObesityActive, not recruitingNCT07000955Phase 1/2
• A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Healthy and Asthmatic ParticipantsCompletedNCT06947408Phase 1
• A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody TherapyActive, not recruitingNCT06945107Phase 3
• A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)Active, not recruitingNCT06937749Phase 2
• A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema（DME）Active, not recruitingNCT06908876Phase 2
• A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）Active, not recruitingNCT06884293Phase 3
• A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With ObesityActive, not recruitingNCT06862908Phase 2
• Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingNCT06834672Phase 3
• This is a Study to Evaluate the Pharmacokinetics and Safety of IBI362 in Chinese Adolescents With ObesityCompletedNCT06536023Phase 1
• A Study of IBI311 in Subjects With Inactive or Active Thyroid Eye DiseaseCompletedNCT06525506Phase 2
• A Dose Finding Study to Assess Efficacy and Safety of IBI128 in Chinese Gout SubjectsCompletedNCT06501534Phase 2
• Safety and Tolerability of IBI355 in Patients With Primary Sjogren's SyndromeCompletedNCT06484855Phase 1
• Safety and Tolerability of IBI355 in Healthy VolunteersCompletedNCT06416787Phase 1
• A Study to Investigate the Pharmacokinetic/Pharmacodynamic Characteristics of IBI128(A New Xanthine Oxidase Inhibitor)CompletedNCT06277752Phase 1
• A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)Active, not recruitingNCT06238843Phase 3
• A First-in-human, Single-ascending-dose Study of IBI3002 in Healthy Participants and Mild to Moderate AsthmaticsCompletedNCT06213844Phase 1
• A Study of IBI3004 in Subjects With Unresectable, Locally Advanced or Metastatic Solid TumorsTerminatedNCT06198426Phase 1/2
• A First In Human (FIH) Study of IBI356 in Healthy Participants and in Atopic Dermatitis PatientsCompletedNCT06193434Phase 1
• A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and ObesityCompletedNCT06184568Phase 3
• A Multicentre,Study of IBI133 in Subjects WithUnresectable, Locally Advanced or Metastatic SolidTumoursCompletedNCT06170190Phase 1/2

← Innovent Biologics, Inc. overview and focus areas